Patents Examined by Samantha L Shterengarts
  • Patent number: 11230534
    Abstract: Disclosed herein are new compounds and compositions and their application as pharmaceuticals for the treatment of diseases. Methods of inhibition of KDM1A, methods of increasing gamma globin gene expression, and methods to induce differentiation of cancer cells in a human or animal subject are also provided for the treatment of diseases such as acute myelogenous leukemia.
    Type: Grant
    Filed: November 1, 2019
    Date of Patent: January 25, 2022
    Assignee: Imago Biosciences, Inc.
    Inventors: Hugh Y. Rienhoff, Jr., John M. McCall, Michael Clare, Cassandra Celatka, Amy E. Tapper
  • Patent number: 11230542
    Abstract: The present disclosure relates generally to therapeutic agents that may be useful as inhibitors of Integrated Stress Response (ISR) pathway.
    Type: Grant
    Filed: December 13, 2018
    Date of Patent: January 25, 2022
    Assignee: PRAXIS BIOTECH LLC
    Inventors: Sebastian Bernales, Luz Marina Delgado Oyarzo, Gonzalo Esteban Núñez Vasquez, Gonzalo Andrés Ureta Díaz, Brahmam Pujala, Dayanand Panpatil, Bhawana Bhatt, Sarvajit Chakravarty
  • Patent number: 11219625
    Abstract: The present invention includes novel compounds and methods for preventing or treating diseases associated with N-linked glycosylation in a subject in need thereof. The methods comprise administering to the subject an effective amount of at least one compound of the invention.
    Type: Grant
    Filed: July 22, 2016
    Date of Patent: January 11, 2022
    Assignees: YALE UNIVERSITY, THE UNIVERSITY OF KANSAS
    Inventors: Joseph N. Contessa, Jennifer E. Golden, Daniel P. Flaherty
  • Patent number: 11207298
    Abstract: Substituted 1H-imidazo[4,5-b]pyridin-2(3H)-ones as NR2B receptor ligands. Such compounds may be used in NR2B receptor modulation and in pharmaceutical compositions and methods for the treatment of disease states, disorders, and conditions mediated by NR2B receptor activity.
    Type: Grant
    Filed: March 3, 2020
    Date of Patent: December 28, 2021
    Assignee: JANSSEN PHARMACEUTICA NV
    Inventors: Christa C. Chrovian, Michael A. Letavic, Jason C. Rech, Dale A. Rudolph, Akinola Soyode-Johnson, Brice M. Stenne, Jessica L. Wall
  • Patent number: 11203579
    Abstract: In one aspect, compounds of Formula AA, or a pharmaceutically acceptable salt thereof, are featured. The variables shown in Formula AA are as defined in the claims. The compounds of formula AA are NLRP3 activity modulators and, as such, can be used in the treatment of metabolic disorders (e.g. Type 2 diabetes, atherosclerosis, obesity or gout), a disease of the central nervous system (e.g. Alzheimer's disease, multiple sclerosis, Amyotrophic Lateral Sclerosis or Parkinson's disease), lung disease (e.g. asthma, COPD or pulmonary idiopathic fibrosis), liver disease (e.g. NASH syndrome, viral hepatitis or cirrhosis), pancreatic disease (e.g. acute pancreatitis or chronic pancreatitis), kidney disease (e.g. acute kidney injury or chronic kidney injury), intestinal disease (e.g. Crohn's disease or Ulcerative Colitis), skin disease (e.g. psoriasis), musculoskeletal disease (e.g. scleroderma), a vessel disorder (e.g. giant cell arteritis), a disorder of the bones (e.g.
    Type: Grant
    Filed: July 23, 2018
    Date of Patent: December 21, 2021
    Assignee: NOVARTIS AG
    Inventors: Luigi Franchi, Shomir Ghosh, Gary Glick, Jason Katz, Anthony William Opipari, Jr., William Roush, Hans Martin Seidel, Dong-Ming Shen, Shankar Venkatraman, David Guenther Winkler
  • Patent number: 11197849
    Abstract: Provided is a pharmaceutical preparation for treatment or prevention of glaucoma or ocular hypertension, comprising 0.0003 to 0.01% (w/v) of isopropyl (6-{[4-(pyrazol-1-yl)benzyl](pyridin-3-ylsulfonyl)aminomethyl}pyridin-2-ylamino)acetate, or a salt thereof.
    Type: Grant
    Filed: May 29, 2020
    Date of Patent: December 14, 2021
    Assignee: SANTEN PHARMACEUTICAL CO., LTD.
    Inventors: Naveed Shams, Henk-Andre Kroon, Hisashi Kawata, Noriko Kawabata
  • Patent number: 11198691
    Abstract: The present invention provides compounds of formula (I): compositions comprising such compounds; the use of such compounds in therapy (for example in the treatment or prevention of a disease or condition in which plasma kallikrein activity is implicated); and methods of treating patients with such compounds; wherein R5, R6, R7, A, B, W, X, Y and Z are as defined herein.
    Type: Grant
    Filed: February 28, 2020
    Date of Patent: December 14, 2021
    Assignee: KalVista Pharmaceuticals Limited
    Inventors: Rebecca Louise Davie, Hannah Joy Edwards, David Michael Evans, Simon Teanby Hodgson
  • Patent number: 11197837
    Abstract: Effective methods and compositions to deter abuse of pharmaceutical products (e.g., orally administered pharmaceutical products) including but not limited to immediate release, sustained or extended release and delayed release formulations for drugs subject to abuse.
    Type: Grant
    Filed: February 27, 2020
    Date of Patent: December 14, 2021
    Assignee: ACURA PHARMACEUTICALS, INC.
    Inventor: Ronald L. Leech, Jr.
  • Patent number: 11191269
    Abstract: The present disclosure is related to the field of agrochemicals, including compound I and its use to control fungal diseases on turfgrasses.
    Type: Grant
    Filed: May 2, 2018
    Date of Patent: December 7, 2021
    Assignee: Dow AgroSciences LLC
    Inventor: James M Breuniger
  • Patent number: 11185531
    Abstract: Described herein are compounds of Formula (I), pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof. Compounds described herein are useful for inhibiting arginine methyltransferase activity. Methods of using the compounds for treating arginine methyltransferase-mediated disorders are also described.
    Type: Grant
    Filed: February 26, 2020
    Date of Patent: November 30, 2021
    Assignee: Epizyme, Inc.
    Inventors: Richard Chesworth, Lorna Helen Mitchell, Gideon Shapiro
  • Patent number: 11186561
    Abstract: Disclosed is a compound of formula I or a pharmaceutically acceptable hydrate, solvate, crystal, co-crystal, enantiomer, stereoisomer, polymorph or prodrug thereof, which is useful for treatment of eye disorders, skin diseases and/or complications associated therewith. Also disclosed is a pharmaceutical composition comprising as an active ingredient at least one compound of formula I and a pharmaceutically acceptable excipient. Also disclosed is a method of treating an eye disorder, skin disease and/or a complication thereof in a subject in need thereof by administering at least one compound of formula I or a pharmaceutically acceptable hydrate, solvate, crystal, co-crystal, enantiomer, stereoisomer, polymorph or prodrug thereof.
    Type: Grant
    Filed: May 7, 2020
    Date of Patent: November 30, 2021
    Assignee: Cellix Bio Private Limited
    Inventor: Mahesh Kandula
  • Patent number: 11180510
    Abstract: The present invention relates to a compound having the following formula (I): (I) wherein: —R is a (C1-C6)alkyl group; —R? is preferably H; —Ar is a (C5-C12)arylene radical; —X1 is —C(?O)—or —SO2—; and —R? is chosen from the group consisting of possibly substituted (C1-C6)alkyl, heteroaryl, (C5-C12)aryl, and (hetero)cycloalkyl groups, or a pharmaceutically acceptable salt and/or tautomeric form thereof, or its racemates, diastereomers or enantiomers.
    Type: Grant
    Filed: November 6, 2018
    Date of Patent: November 23, 2021
    Assignees: CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE, UNIVERSITÉ D'AIX-MARSEILLE, INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM)
    Inventors: Stéphane Betzi, Sébastien Combes, Yves Collette, Laurent Hoffer, Xavier Morelli, Brigit Raux, Philippe Roche, Iuliia Voitovich
  • Patent number: 11179370
    Abstract: The present invention provides novel, diastereomeric pyrazolines that are useful as cannabinoid receptor blockers and pharmaceutical compositions thereof and methods of using the same for treating obesity, diabetes, inflammatory disorders, cardiometabolic disorders, hepatic disorders, and/or cancers.
    Type: Grant
    Filed: March 4, 2020
    Date of Patent: November 23, 2021
    Assignee: Jenrin Discovery, LLC
    Inventors: John F McElroy, Robert J. Chorvat
  • Patent number: 11180438
    Abstract: The present invention relates to polyhydroxylated benzophenone compounds useful in the treatment of neurodegenerative, neurological, psychiatric, and cognitive diseases, in particular those associated with a deficiency in HDAC1 deacetylase activity.
    Type: Grant
    Filed: June 15, 2018
    Date of Patent: November 23, 2021
    Assignees: Massachusetts Institute of Technology, The General Hospital Corporation
    Inventors: Li-Huei Tsai, Stephen J. Haggarty, Debasis Patnaik, Ping-Chieh Pao
  • Patent number: 11180479
    Abstract: The present invention relates to novel compounds of general formula (I) wherein R1 to R4 and n have the meanings given in the description and claims, process for preparing these compounds and their use as for treating, preventing or ameliorating viral infections and their use for treating, preventing or ameliorating diseases which are associated with PLA2G16.
    Type: Grant
    Filed: October 5, 2018
    Date of Patent: November 23, 2021
    Assignee: HAPLOGEN GMBH
    Inventors: Wolfgang Fischl, Christopher John Yarnold, Patricia Leonie Amouzegh, Kevin Thewlis, Jon Shepherd, Mark Anthony Kerry
  • Patent number: 11174248
    Abstract: The present invention is directed to substituted certain reversed indazole compounds of Formula (I): and pharmaceutically acceptable salts thereof, wherein R1A, R1B, X, Y, RZ and R2 are as defined herein, which are potent inhibitors of LRRK2 kinase and useful in the treatment or prevention of diseases in which the LRRK2 kinase is involved, such as Parkinson's Disease and other diseases and disorders described herein. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which LRRK-2 kinase is involved.
    Type: Grant
    Filed: October 8, 2018
    Date of Patent: November 16, 2021
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: John Acton, David Annunziato Candito, J. Michael Ellis, Peter H. Fuller, Hakan Gunaydin, Blair T. Lapointe, Weiguo Liu, Joey L. Methot, Santhosh F. Neelamkavil, Barbara Pio, Vladimir Simov, Harold B. Wood
  • Patent number: 11173217
    Abstract: Disclosed herein is a donor-acceptor-donor (D-A-D) compound of formula I, where in the acceptors are mono-substituted tetraphenylethylene moieties. Also disclosed herein are fluorescent nanodots that comprise the compound of formula (I) and uses of said compound or nanodots in in vivo imaging or detecting of cancer cells in a subject.
    Type: Grant
    Filed: August 10, 2017
    Date of Patent: November 16, 2021
    Assignee: NATIONAL UNIVERSITY OF SINGAPORE
    Inventors: Bin Liu, Jie Liu
  • Patent number: 11166942
    Abstract: The present disclosure relates generally to therapeutic agents that may be useful as inhibitors of Integrated Stress Response (ISR) pathway.
    Type: Grant
    Filed: June 5, 2019
    Date of Patent: November 9, 2021
    Assignee: PRAXIS BIOTECH LLC
    Inventors: Luz Marina Delgado Oyarzo, Gonzalo Andrés Ureta Díaz, Brahmam Pujala, Dayanand Panpatil, Sebastian Bernales, Sarvajit Chakravarty
  • Patent number: 11168078
    Abstract: Provided are certain IDO inhibitors or pharmaceutically acceptable salts thereof which can inhibit enzymatic activity of indoleamine 2,3-dioxygenase (IDO) and may be useful for the treatment of diseases and disorders mediated by IDO. In addition, pharmaceutical compositions thereof and methods of use thereof are also provided.
    Type: Grant
    Filed: November 28, 2017
    Date of Patent: November 9, 2021
    Assignees: Shanghai Fochon Pharmaceutical Co., Ltd., Fochon Pharmaceuticals, Ltd.
    Inventors: Zhifang Chen, Rui Tan, Qihong Liu, Lijun Yang, Zhifu Li, Haohan Tan, Hongbin Liu, Xingdong Zhao, Min Lin, Jing Sun, Weibo Wang
  • Patent number: 11168065
    Abstract: The invention relates to the compounds of formula I, formula II, formula III, formula IV, formula V, formula VI, formula VII and formula VIII, or its pharmaceutical acceptable polymorphs, solvates, enantiomers, stereoisomers and hydrates thereof. The pharmaceutical compositions comprising an effective amount of compounds of formula I, formula II, formula III, formula IV, formula V, formula VI, formula VII and formula VIII, and methods for the treatment of mucositis may be formulated for oral, mouth wash, buccal, rectal, topical, transdermal, transmucosal, intravenous, oral solution, buccal mucosal layer tablet, parenteral administration, syrup, or injection. Such compositions may be used to treatment of oral and gastrointestinal mucositis, mucosal inflammatory and oral infectious diseases.
    Type: Grant
    Filed: January 19, 2016
    Date of Patent: November 9, 2021
    Assignee: Cellix Bio Private Limited
    Inventor: Mahesh Kandula